Document is current
Any future updates will be listed below
-
Authors
Roll, Matthias
Gladbach, Amadeus
Selinger, Isabella
Hardt, Thomas
Himmelhaus, Helena
Jacob, Christian
Stremel, Timotheus
Theil, Julia
Floege, Jürgen
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 20 June 2025
First Online: 3 July 2025
Declarations
:
: Claims data from the participating SHIs are joined in a specialized trust centre, anonymized, and transferred to InGef before the data are made available for research. The analysis of claims data from the SHI is fully compliant with German federal law and in accordance with the “GPS – Good Practice in Secondary Data Analysis” (Guideline 1: Ethics), the approval of an ethics committee and informed consent of the patients were not required.
: Not applicable.
: Matthias Roll, Amadeus Gladbach, Isabella Selinger and Thomas Hardt are full-time employees of CSL Vifor. Helena Himmelhaus, Christian Jacob, Timotheus Stremel and Julia Theil are a full-time employees of PharmaLex GmbH, part of Cencora Inc., acting as contractors of CSL Vifor for the execution of this study. Jürgen Floege has received consultancy and/or lecture fees from AstraZeneca, Bayer, Boehringer, CSL Vifor, HiBio, Novartis, Roche, Stadapharm, Travere, Vera Therapeutics and serves on data safety monitoring boards of NovoNordisk and Visterra.
